Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

News In Brief

This article was originally published in The Silver Sheet

Executive Summary

Firms with an egregious state of quality control might be able to enter into remediation agreements with FDA; agency might ease up on direct marking of devices in final UDI rule; and more.

Advertisement

Related Content

Year In Review: Complaint Handling, UDI, FDA Inspections, And More
News In Brief
FDA Launches Voluntary Compliance Improvement Pilot
FDA’s Latest Post-Market Plan: Data-Mining Device Safety … And Then There’s MAUDE
Anatomy Of A Unique Device Identifier: It’s Flexible
Advertisement
UsernamePublicRestriction

Register

MT036700

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel